Broadly neutralizing antibodies (bnAbs) against HIV exist in humans, but inducing them by vaccination has been one of the central challenges in HIV vaccine development.
For many years, numerous immunological hurdles were thought to make this goal extraordinarily difficult—and perhaps unattainable.
